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Vincristine is one of the commonest chemotherapeutic agents in the practice of pediatric oncology.
Although peripheral neuropathy is a dose limiting adverse event, blindness secondary to vincristine is
seldom reported. We describe a child with Wilms tumor who developed transient visual loss after
administration of vincristine. The child underwent early surgery and vincristine was re-introduced at
reduced doses and gradually escalated to full dose while closely monitoring for recurrence. Blindness is a
distressing adverse event, and re-exposure to the offending agent involves a conscientious decision.
© 2016 Pediatric Hematology Oncology Chapter of Indian Academy of Pediatrics. Production and hosting
by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).Vincristine is ubiquitous in the practice of pediatric oncology.
Although vincristine induced neuropathy is a well-known dose
limiting side effect, blindness is rarely reported [1,2]. Vincristine
exposure can potentially lead to transient or permanent blindness
by mechanisms including cranial neuropathy, optic nerve atrophy
and cortical blindness [2,3]. We describe a child with transient,
cortical blindness secondary to vincristine.
A 7-year old boy was diagnosed with left sided Wilms' tumor
(WT). He was treated as per the International Society of Pediatric
Oncology Wilms' Tumor protocol (SIOP-WT2001) [4]. Twenty-four
hours following the ﬁrst dose of neoadjuvant chemotherapy
(NACT) comprising vincristine (1.5 mg/m2, intravenous bolus) and
actinomycin-D, he presented with sudden, complete loss of vision.
There was no association with headache, vomiting, altered senso-
rium or seizures. On examination, patient was normotensive and
fundus was normal. Pupillary reﬂex was intact. Neurological ex-
amination revealedno cranial neuropathy, sensoryormotordeﬁcits.
He was euglycaemic, with normal serum electrolytes. Contrast
enhancedcomputerized tomographyof theheadwasnormal.Aftera
duration of 4 h, vision recovered completely. He experienced tran-
sient dizziness after the second dose of vincristine, administeredtrehan.amita@pgimer.edu.in,
atology Oncology Chapter of
apter of Indian Academy of Pediatr
enses/by-nc-nd/4.0/).after oneweek. The third vincristinewas uneventfully administered
at 50% dose, following which he underwent radical nephrectomy.
Histopathological examination of the tumor revealed intermediate
risk histology. He received 27 weeks of adjuvant chemotherapy
(ACT) with vincristine and actinomycin-D as a stage II tumor [4]. He
received 50% doses of vincristine in the ﬁrst 4 weeks of ACT.
Thereafter, doses were escalated gradually to achieve full dose by
week 11. Two months following completion of therapy, he had a
localized relapse. He was successfully salvaged with chemotherapy
and local radiotherapy, based on the United Kingdom Children's
Cancer and Leukemia Group protocol for relapsed WT [5]. He has
been well and disease free for the last 1 year.
Vincristine can cause inhibition of microtubule polymerization,
direct axonal injury in the retina, optic nerve ischemia and loss of
neuro-synaptic activity [2,3,6]. The risk of neurotoxicity is
increased in patients with liver dysfunction, pre-existing neuro-
logical disorders and malnutrition [1,7]. A wide range of ocular side
effects, such as cranial neuropathy manifesting as ptosis, lagoph-
thalmos and corneal hyperesthesia; optic atrophy; cortical blind-
ness and nyctalopia has been reported in association with
vincristine [2,3,6,8e11]. Blindness is an uncommon manifestation
of vincristine induced neurotoxicity, described in few case reports
and small case series [1,2,8e10]. Cortical blindness is characterized
by complete loss of visual sensation, including perception of light;
with the preservation of pupillary reﬂex and eye motility; and a
normal retinal examination [1]. Vincristine induced cortical blind-
ness is largely reversible with the discontinuation of the offendingics. Production and hosting by Elsevier B.V. This is an open access article under the
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albeit to a lesser extent [2,8]. Re-challenge with reduced dose of
vincristine is a conscientious decision which has to balance cure
with the risk of recurrence of a potentially disabling adverse event.
An early nephrectomy was done in the index patient after 3 weeks
of NACT instead of the standard 4 weeks. Subsequently, gradually
escalated doses of vincristine were administered without any
recurrence of visual symptoms. However, the reduced doses may
have contributed to relapse in this patient.
It is essential to be perceptive of vincristine induced blindness
and withhold vincristine promptly on its occurrence. Re-exposure
at reduced dose involves a cautious and individualized decision.
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